Cerevel Therapeutics Holdings Inc
(NAS:CERE)
$
41.65
-0.03 (-0.07%)
Market Cap: 7.59 Bil
Enterprise Value: 7.12 Bil
PE Ratio: 0
PB Ratio: 13.44
GF Score: 40/100 - Abbvie Inc To Acquire Cerevel Therapeutics TranscriptDec 07, 2023
- Q3 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptNov 01, 2023$25.35 (+7.19%)Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptAug 02, 2023$26.33 (-14.09%)Earnings
- Cerevel Therapeutics Holdings Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptMay 03, 2023$31.92 (+3.32%)Earnings
- Cerevel Therapeutics Holdings Inc at Stifel CNS Days (Virtual) TranscriptMar 29, 2023
- Cerevel Therapeutics Holdings Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptFeb 22, 2023$26.73 (-13.77%)Earnings
- Cerevel Therapeutics Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Q3 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptNov 08, 2022$25.7 (-5.20%)Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptAug 01, 2022$27.66 (+5.21%)Earnings
- Q1 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptMay 10, 2022$22.68 (+2.25%)Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Cerevel Therapeutics Holdings Inc at Citi BioPharma Conference (Virtual) TranscriptSep 08, 2021
- Cerevel Therapeutics Holdings Inc R&D Event TranscriptJan 28, 2021
Cerevel Therapeutics Holdings Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023 / 05:00PM GMT
Release Date Price:
$31.98
(-2.59%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Everybody, good morning. Thanks for joining us. Welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMID Biotech analysts here. It's my pleasure to have with us our next presenting company, Cerevel Therapeutics.
Presenting for Cerevel this morning is now outgoing CEO, Tony Coles. So I do have a list of questions. Maybe you can start off, Tony, by giving us an overview of the company. And then I guess, from those who didn't listen to the earnings call, talk to us about why you think now is the right time to transition the CEO seat. You'll still be with the company, of course, with the Board.
N. Anthony Coles
Cerevel Therapeutics Holdings, Inc. - Executive Chairman & CEO
As chair.
Questions & Answers
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
How do you envision your role at the company continuing going
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)